Is Cellebrite DI (CLBT) A Bargain After Guardian Clearance And C TEK Launch?
Cellebrite DI (CLBT) is back on investor radars after two product updates. Its Guardian evidence platform cleared an Australian IRAP PROTECTED assessment, and the new C TEK field kit broadens the company’s defense focused offering.
Cellebrite DI’s share price has come under pressure in recent months, with the stock down 28.48% on a 1 month share price return basis and 35.82% year to date, even though the 3 year total shareholder return of 45.30% is still positive. Recent product news on Guardian and C TEK arrives against that backdrop, and the weaker short term share price performance suggests investors are reassessing near term growth expectations or risk around the story despite those product milestones.
Compare Cellebrite DI’s recent pullback and product momentum with a hand picked 17 high quality undiscovered gems that also focus on high value software and digital evidence workflows.
Cellebrite DI appears to be a focused digital forensics business, yet the stock has fallen sharply in recent months. After that pullback and recent product news on Guardian and C TEK, an important question is whether the current valuation is attractive or still demanding.
Most Popular Narrative: 25.4% Undervalued
Cellebrite DI's most followed valuation narrative puts fair value at $15.36 versus the last close at $11.45, which frames the recent share price pullback in a very different light.
The continued transition to a recurring, subscription-based revenue model with over 90% of revenues now from subscriptions and growing SaaS/cloud penetration improves revenue visibility, predictability, and operating leverage, which is already translating into higher EBITDA and free cash flow margins and is likely underappreciated in current valuations.
Want to see what sits behind that confidence in Cellebrite DI's subscription engine? The narrative focuses on compound earnings growth, firmer margins, and a punchy future profit multiple.
Result: Fair Value of $15.36 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this Cellebrite DI narrative still faces meaningful risks if U.S. federal spending remains slow or if stricter privacy rules curb demand for digital evidence tools.
Find out about the key risks to this Cellebrite DI narrative.
Another View on Cellebrite DI’s Valuation
The analyst narrative sees Cellebrite DI trading below fair value at $15.36, but the current P/E of 49.3x sends a different signal. That compares with an estimated fair ratio of 35.6x, a peer average of 42.3x, and a US Software industry average of 31.2x. That gap points to valuation risk if sentiment weakens again. Which signal do you trust more?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With mixed signals around Cellebrite DI's valuation and outlook, it can be helpful to review the details yourself before sentiment shifts again. To balance the debate on risks and upside, start with the 4 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Cellebrite DI?
If you are only focused on Cellebrite DI, you could miss other stocks that fit your style. Use the Simply Wall Street Screener to surface fresh ideas efficiently.
- Target resilient income by reviewing companies in the 11 dividend fortresses that could help anchor your portfolio with higher yielding payers.
- Spot potential value opportunities early by scanning the 47 high quality undervalued stocks where strong fundamentals and compressed valuations sit side by side.
- Strengthen your watchlist with financially robust businesses by checking the list of solid balance sheet and fundamentals (53 results) so you do not overlook sturdier balance sheets.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com